Predicting the Safety and Effectiveness of Inferior Vena Cava Filters (PRESERVE)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02381509 |
Recruitment Status :
Completed
First Posted : March 6, 2015
Last Update Posted : October 4, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Pulmonary Embolism Deep Vein Thrombosis | Device: IVC Filter |
The overall goal is to characterize the current practice of IVC filter placement, including the indications, filter type, frequency and success of filter removal, safety of placement initially and in the long term, including filter mechanical stability and caval patency, and the frequency of subsequent episodes of PE and recurrence of DVT. The first steps are to identify the characteristics of use in a broad range of clinical practice settings in the US.
Commercially available IVC filters from 6 manufacturers in the United States will be used. The type of FDA-cleared IVC filter implanted will be left to the discretion of the Principal Investigator at the Site. The following IVC filters will be utilized in this trial:
- ALN Vena Cava Filter (with and without hook) (ALN Implants Chirurgicaux)
- Option™ Elite Retrievable Vena Cava Filter (Argon Medical Devices Inc., designed and manufactured by Rex Medical)
- VenaTech® LP Vena Cava Filter (B Braun Interventional Systems, Inc.) and VenaTech® Convertible™ Vena Cava Filter
- DENALI® Vena Cava Filter System (DL900F, DL900J) (Bard Peripheral Vascular, Inc.)
- Cook Günther-Tulip™ Vena Cava Filter (Cook Incorporated)
- Cordis OPTEASE® Retrievable Vena Cava Filter and Cordis TRAPEASE® Permanent Vena Cava Filter (Cordis Corporation)
Subjects will be evaluated at Procedure, Discharge, 3-months, 6-months (phone), 12-months, 18-months (phone), and 24-months post-procedure. All subjects in whom the IVC filter is removed will be followed for 1-month postretrieval. Mandated follow-up imaging will be performed at 3 months (plain film) and 12 and 24 months (contrast abdominal CT). In addition, clinical visits with physical exam will be performed at 3 months, 12 months and 24 months.
Study Type : | Observational |
Actual Enrollment : | 1428 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | Predicting the Safety and Effectiveness of Inferior Vena Cava Filters |
Actual Study Start Date : | October 2015 |
Actual Primary Completion Date : | March 17, 2020 |
Actual Study Completion Date : | September 20, 2021 |

Group/Cohort | Intervention/treatment |
---|---|
IVC Filter
IVC filter for the prevention of PE
|
Device: IVC Filter |
- Composite safety endpoint of freedom from clinically significant perforation after successful filter placement, filter embolization, caval thrombotic occlusion, deep vein thrombosis, and perioperative serious adverse event [ Time Frame: Within first 365 days (± 30 days) ]Clinically significant perforation is defined as protrusion of filter legs through the wall of the IVC causing hemorrhage or hematoma or touching, impressing, or perforating another organ or that triggers the decision to remove the filter; resulting in an attempt to remove the IVC filter or requiring other intervention. Filter embolization is defined as movement of the filter or its components to a distant anatomic site completely out of the target zone after successful filter placement, confirmed by imaging. Caval thrombotic occlusion is defined as presence of an occluding thrombus in the IVC after filter insertion and documented by ultrasound (US), computed tomography (CT), magnetic resonance (MR) imaging, venography, or autopsy; this may be symptomatic or asymptomatic after successful filter placement. Deep vein thrombosis (DVT) is defined as new symptomatic DVT post-deployment, as determined by standard of care imaging. Serious adverse event is defined by ISO 14155.
- Composite effectiveness endpoint of procedural and technical success without occurrence of clinically significant pulmonary embolism [ Time Frame: At 12-months in-situ or 1-month post-retrieval (whichever comes first) ]New symptomatic PE confirmed by appropriate imaging
- Mechanical Stability [ Time Frame: At 3-months, 6-months, 12-months, 18-months, 24-months or at the time of filter retrieval ]Defined by absence of: 1) Migration: cephalad movement of the filter >20mm relative to fixed anatomic landmarks compared to the time of placement, 2) Migration: caudal migration of the filter >20mm relative to fixed anatomic landmarks compared to the time of placement, 3) Perforation: >5mm outside apparent cava wall as determined by CT or perforation of adjacent viscera or major vessel, 4) Filter fracture: any loss of a filter's structural integrity (i.e. breakage or separation) documented by imaging or autopsy, 5) Filter embolization: post-deployment movement of the filter or its components to a distant anatomic site completely out of the target zone
- Procedure-related complications [ Time Frame: At 3-months ]In the judgment of the Principal Investigator
- Major adverse events (composite and individual components) [ Time Frame: At 3-months, 6-months, 12-months, 18-months, and 24-months ]Defined as death, PE, caval thrombotic occlusion, DVT, clinically significant perforation, retroperitoneal hematoma, or adjacent organ penetration
- Filter tilting >15° [ Time Frame: At 3-months, 6-months, 12-months, 18-months, 24-months or at the time of filter retrieval ]As determined by appropriate imaging
- Filter retrieval [ Time Frame: Up to 24-months ]Includes: Attempted retrieval, Successful retrieval, Failed retrieval, Percentage of retrieval success, Complications associated with filter retrieval, Reasons for failed retrieval
- Secondary Effectiveness Endpoint for each IVC filter brand tested only if the study is a success (i.e., both primary safety and effectiveness endpoints have been met) [ Time Frame: At 12-months ]PE rate

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Male or Female, age 18 years or older;
- Requires IVC filter for prevention of pulmonary embolism (PE);
- Provide written informed consent and written HIPAA authorization prior to initiation of study procedures;
- Willing to comply with the specified follow-up
Exclusion Criteria:
- Subject is unable to participate in study evaluations pre- and post-treatment
- Known sensitivity to contrast or serious contrast reaction such as anaphylaxis for which premedication is known to be unsuccessful in alleviating symptoms

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02381509

Study Chair: | David L. Gillespie, MD, FACS | Cape Cod Hospital | |
Study Chair: | Matt Johnson, MD | Indiana University School of Medicine |
Responsible Party: | HealthCore-NERI |
ClinicalTrials.gov Identifier: | NCT02381509 |
Other Study ID Numbers: |
M01482 |
First Posted: | March 6, 2015 Key Record Dates |
Last Update Posted: | October 4, 2021 |
Last Verified: | September 2021 |
Studies a U.S. FDA-regulated Drug Product: | No |
inferior vena cava filters |
Pulmonary Embolism Thrombosis Embolism Venous Thrombosis Embolism and Thrombosis |
Vascular Diseases Cardiovascular Diseases Lung Diseases Respiratory Tract Diseases |